JonesResearch downgraded Chimerix (CMRX) to Hold from Buy with an $8.55 price target after Jazz Pharmaceuticals (JAZZ) announced a deal to acquire the company for $8.55 per share or $935M in cash.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMRX:
- Strategic Acquisition and NDA Submission Boost Chimerix’s Market Potential
- Cautious Outlook on Chimerix Amid Acquisition and Uncertainties in Drug Approval
- Chimerix downgraded to Hold from Buy at Jefferies
- CrowdStrike reports Q4 beat, Jazz to acquire Chimerix: Morning Buzz
- Hold Rating Issued Amidst Chimerix Acquisition by Jazz Pharmaceuticals
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue